Abstract
A significant growth of bacterial resistance to antimicrobial agents has been reported globally over the past decades. Pneumococcus and Haemophilus influenzae are the major respiratory and ENT pathogens among children in the Russian Federation. To date, the problem of rational and effective bacterial respiratory tract infections therapy remains unsettled. The emergence of the new high-dose amoxicillin with clavulanate provides additional opportunities for respiratory disease therapy in children with risk factors for drug-resistant pathogens.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
